J. Mark Fitzgerald, M.D.
Dr. J. Mark FitzGerald is a Consultant Respiratory Physician at The Lung Centre, Vancouver General Hospital, and Professor of Medicine and head of the UBC Respiratory Medicine program at the University of British Columbia. He is the founding Director of the UBC Centre for Lung Health and co-Director of the newly formed Institute for Heart and Lung Health at UBC. He has an extensive program of clinical research in asthma, COPD, tuberculosis, and health outcomes. He has worked with national and international groups to develop evidence based asthma guidelines. He is a member of the CTS Executive and it’s Asthma Committee and has worked with the Canadian Asthma Guidelines working group since 1989. He is a member of the Global Initiative in Asthma (GINA), Executive, and Chair of its Science Committee. He has published over 280 peer reviewed papers and editorials.
Bruce Montgomery, M.D.
Dr. Montgomery is both a physician scientist and an entrepreneur that has been a leader in bringing new discoveries related to pulmonary and critical care medicine to the bedside. He has led development teams for new medical therapies for patients with cystic fibrosis, including Cayston, TOBI, and Pulmozyme. all improve respiratory symptoms in cystic fibrosis patients. In the 1980’s he co-invented aerosolized pentamidine, a prophylaxis for PCP, then the most common cause of death in patients with AIDS. He is an inventor on 18 US patents. He has been a CEO or the research head of three Seattle based biotech companies. Dr. Montgomery received his B.S. in Chemistry and M.D. degrees from the University of Washington and is a board-certified internist and pulmonologist. In 2012, he was recognized by the UW as a recipient of a timeless awards honouring the top 150 living graduates of the college of arts and sciences.
Revati Shreeniwas, M.D.
Clinical Development Advisor
Dr. Revati Shreeniwas has over twenty years of clinical and drug development experience and has held positions of increasing responsibility as Director, Clinical Research at CV Therapeutics, and Senior Director, Clinical Research and Development at Actelion Inc, and Scios, a subsidiary of Johnson and Johnson. Dr. Shreeniwas was President of Revati, Inc., a consulting group where she was responsible for providing strategic consulting to life sciences companies. Dr. Shreeniwas has also served on the faculties of Columbia University and Stanford University.
Matthias Amrein, PhD
Dr. Amrein is the founder of SolAeroMed’s S1229 drug technology. He is a professor at the Faculty of Medicine, University of Calgary, Snyder Institute for Chronic Diseases, Airway Inflammation Research Group (AIRG). He studied at the Swiss Federal Institute of Technology, Zurich (ETH) with a doctorate from a joint venture between the IBM research lab in Rueschlikon (group of Nobel Laureate Heinrich Rohrer) and ETH, where he was the first to successfully apply the then new scanning probe technique (STM, AFM) to the biomedical area. In his current function as a member of the AIRG, he credits his group with discovering the main mechanism of pulmonary surfactant dysfunction with a treatment in pre-clinical testing. He is the director of the Microscopy and Imaging Facility (MIF), University of Calgary. This University wide facility for electron-, atomic force- and super resolution light microscopy serves researchers from more than 100 industry and academic labs from medicine, biological sciences and engineering.